A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

  • participants needed
  • sponsor
    Zhejiang Cancer Hospital
Updated on 6 December 2021


To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma


The purpose of this study was to evaluate the efficacy and safety of bortezomib combined with CHEP in patients with peripheral T cell lymphoma. Primary end point of this study were objective response rate including complete remission rate and partial remission rate.

Condition Peripheral T-Cell Lymphoma, T-Cell Lymphoma
Treatment cyclophosphamide, etoposide, prednisone, Bortezomib, pharmorubicin
Clinical Study IdentifierNCT04061772
SponsorZhejiang Cancer Hospital
Last Modified on6 December 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note